Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
| ▸ | YAP1 | P46937 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122829 | 0.92 | GPR132 (0.57) | GAALMNAMAPTNPSR1PPARG | |
| SCHEMBL1123055 | 0.85 | GAA (0.80) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL1122834 | 0.82 | GAA (0.75) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL1122925 | 0.82 | GAA (0.75) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL1123370 | 0.81 | GAA (0.73) | GAARAB9ALMNAMAPTPPARG | |
| SCHEMBL6030161 | 0.81 | GAA (0.77) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL1123147 | 0.79 | GAA (0.71) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL1123382 | 0.79 | GAA (0.71) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL27638047 | 0.79 | RAB9A (0.74) | GAARAB9ALMNAPPARGERAP2 | |
| SCHEMBL1122610 | 0.79 | RAB9A (0.74) | GAARAB9ALMNAPPARGERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | GAA 3048/4885RAB9A 4567/4885LMNA 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.